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Jnk2 deficiency increases the rate of
glaucomatous neurodegeneration in ocular
hypertensive DBA/2J mice
Jeffrey M. Harder 1, Pete A. Williams 1, Ileana Soto2, Nicole E. Foxworth1, Kimberly A. Fernandes3,
Nelson F. Freeburg1, Richard T. Libby3 and Simon. W. M. John1,4,5
Abstract
The cJun N-terminal kinases (JNKs; JNK1, JNK2, and JNK3) promote degenerative processes after neuronal injury and in
disease. JNK2 and JNK3 have been shown to promote retinal ganglion cell (RGC) death after optic nerve injury. In their
absence, long-term survival of RGC somas is significantly increased after mechanical optic nerve injury. In glaucoma,
because optic nerve damage is thought to be a major cause of RGC death, JNKs are an important potential target for
therapeutic intervention. To assess the role of JNK2 and JNK3 in an ocular hypertensive model of glaucoma, null alleles
of Jnk2 and Jnk3 were backcrossed into the DBA/2J (D2) mouse. JNK activation occurred in RGCs following increased
intraocular pressure in D2 mice. However, deficiency of both Jnk2 and Jnk3 together did not lessen optic nerve
damage or RGC death. These results differentiate the molecular pathways controlling cell death in ocular hypertensive
glaucoma compared with mechanical optic nerve injury. It is further shown that JUN, a pro-death component of the
JNK pathway in RGCs, can be activated in glaucoma in the absence of JNK2 and JNK3. This implicates JNK1 in
glaucomatous RGC death. Unexpectedly, at younger ages, Jnk2-deficient mice were more likely to develop features of
glaucomatous neurodegeneration than D2 mice expressing Jnk2. This appears to be due to a neuroprotective effect of
JNK2 and not due to a change in intraocular pressure. The Jnk2-deficient context also unmasked a lesser role for Jnk3
in glaucoma. Jnk2 and Jnk3 double knockout mice had a modestly increased risk of neurodegeneration compared
with mice only deficient in Jnk2. Overall, these findings are consistent with pleiotropic effects of JNK isoforms in
glaucoma and suggest caution is warranted when using JNK inhibitors to treat chronic neurodegenerative conditions.
Introduction
Glaucoma is a common neurodegenerative disease that
causes vision loss, affecting millions of people worldwide1.
Glaucomatous degeneration includes loss of retinal
ganglion cell (RGC) somas in the retina and loss of their
axons, which extend from the retina into the optic nerve
and brain. In glaucoma, RGC axons show early signs of
damage in the lamina, the region where RGC axons exit
the eye2–6. Damage at this site is important because it may
trigger the molecularly distinct degeneration processes
that occur on each side of this site7–10. In the DBA/2J (D2)
mouse model of glaucoma, genetically disrupting Bax
prevents loss of RGC somas (RGC death) and their axons
up to the lamina; however, it does not stop degeneration
of the optic nerve outside of the eye and distal to this site
of injury8. Furthermore, the expression of WldS, a muta-
tion that protects against axonal degeneration, can curb
early damage to RGC axons in the lamina11 and protect
RGCs and the optic nerve4,11. Thus, identifying the
molecular mechanism(s) that leads to progressive axon
damage in the lamina is an important step toward
developing neuroprotective glaucoma treatments.
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The cJun N-terminal kinase (JNK) signaling pathway
regulates how various neurons respond to axon damage12.
In RGCs, severe axon trauma activates a specific subset of
JNK signaling pathway members ahead of cell death.
Consistent with specific JNK signaling pathway members
causing RGC death, disrupting the upstream kinase dual
leucine zipper kinase (DLK encoded by Map3k12), or the
downstream JNK target JUN, lessens RGC death after
mechanical optic nerve injury13–18. JNK itself is a product
of three distinct mitogen-activated protein kinase genes
(Mapk8, Mapk9, and Mapk10, encoding JNK1, JNK2, and
JNK3, respectively, and referred to as Jnk1, Jnk2, and Jnk3
in this article), all of which are expressed in the nervous
system19. DLK and JUN are linked in the axon injury-
induced RGC death pathway by JNK2 and JNK314,17. The
combined absence of JNK2 and JNK3 prevents JUN
activation and RGC death after mechanical optic nerve
injury similar to deficiencies in Map3k12 or Jun. It is
hypothesized that a similar cell death pathway is activated
by axon damage in the lamina that occurs in glaucoma.
Jun deficiency has been recently shown to lessen RGC
death in D2 mice with glaucoma15 and other molecules in
the JNK signaling pathway are implicated in glaucoma as
well20–22. Thus, to better understand the function of JNKs
in glaucoma, we tested the function of JNK2 and JNK3 in
DBA/2J mice, an ocular hypertensive model of glau-
coma23–26.
Results
IOP elevation activates JNK signaling in the retina and
optic nerve
Using D2 and D2-Gpnmb+ mice, we assessed whether
RGCs expressed JNK signaling pathway genes during the
window of ocular hypertension in D2 mice. By 9 months
of age (mos), most D2 eyes have ongoing periods of ele-
vated intraocular pressure (IOP), but typically no optic
nerve damage or RGC death25. At this age, many eyes
have gene expression differences compared with age-
matched D2-Gpnmb+ eyes that do not develop high IOP
and glaucoma4,27–30. Previously, RNA-seq-based tran-
scriptomes of RGCs purified from D2 and D2-Gpnmb+
eyes at 9 mos of age were assembled29. In ocular hyper-
tensive eyes, RGCs express a number of JNK signaling
pathway genes previously implicated in the axon injury-
induced RGC death pathway (Fig. 1a). A significant dif-
ference in the expression of Jnk2 and Jun exists between
D2 and D2-Gpnmb+ RGCs (false discovery rate (FDR) <
0.05).
To further examine JNK signaling in glaucoma, we
determined if JNK and JUN were phosphorylated in the
retina using immunohistochemistry (pJNK and pJUN,
respectively, phosphorylation induces an activated state).
At 9 mos of age, pJNK was present in the nerve fiber layer
and optic nerve head (ONH, Fig. 1b) in D2 eyes, but was
undetectable in control D2.Gpnmb+ eyes. pJUN-positive
cells were detectable throughout the ganglion cell layer at
10 mos in D2 eyes, but not in D2.Gpnmb+ eyes (Fig. 1c).
These data are consistent with recent findings, which
Fig. 1 JNK pathway genes associated with axon injury in RGCs
are expressed and activated during D2 glaucoma at 9 months of
age. a Publically available RNA-sequencing data sets from RGCs were
assessed for expression of a subset of JNK signaling pathway genes
implicated in axon injury. RGCs from a group of D2 eyes with ocular
hypertension, but not optic nerve damage were compared with RGCs
from control D2-Gpnmb+ eyes that do not have high intraocular
pressure or develop glaucoma. The D2 eyes analyzed here belong to
the group of eyes with the earliest detected changes in this model
(Group 2,29). The Tukey-style box plots were generated in R. The thick
bar represents median expression level and the hinges correspond to
the first and third quartiles. Whiskers represent 1.5 × the interquartile
range, with outlying data points plotted individually. Expression level
is shown as log counts per million (log2CPM). Significant differences in
expression of Jnk2 and Jun were detected. b Phosphorylated S63 pan-
JNK immunoreactivity (pJNK, red) in ocular hypertensive (D2) and
normotensive (D2-Gpnmb+) eyes was assessed by fluorescence in
cross-sections that include the retina and the optic nerve head (ONH).
The nerve fiber layer (NFL) is filled by RGC axons as they extend
toward the ONH. DAPI (blue) labeling of nuclei was used as a
counterstain. c Phosphorylated JUN immunoreactivity (pJUN, red) in
the ganglion cell layer was assessed by fluorescence in retinal flat
mounts with DAPI (blue) used as a counterstain. Representative
images from ocular hypertensive (D2) and normotensive (D2-
Gpnmb+) eyes are shown. *FDR < 0.05. Scale bar: 50 μm b, 25 μm c
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showed pJUN in TUJ1+ RGCs in glaucomatous DBA/2J
mice15. Together, these data indicate that the JNK sig-
naling pathway responds to elevated IOP with changes in
both expression level and activation state of key
molecules.
Jnk2 and Jnk3 deficiencies do not prevent pigment disease
or IOP elevation in DBA/2J mice
Ocular hypertension in D2 mice occurs secondary to a
pigment dispersing iris disease23,25. D2 mice carrying null
alleles of Jnk2 and Jnk3 were used to test the role of JNK2
and JNK3 in glaucoma and were maintained in a single
mouse colony. As no haploinsufficiency induced pheno-
types have been reported for Jnk2 and Jnk3, D2 mice with
one or more functional copies (+/+ or +/−) of both Jnk2
and Jnk3 were grouped together as control mice in this
study. D2.Jnk2−/− mice were either wild-type or hetero-
zygous for Jnk3. Similarly, D2.Jnk3−/− mice were either
wild-type or heterozygous for Jnk2. Eyes of all genotypes
were carefully assessed for the iris disease and IOP ele-
vation. No differences in iris disease occurred between
genotypes (Fig. 2). The iris disease in eyes of all genotypes
(n= 40 eyes/group) was readily apparent between 6 and 7
mos and most eyes had severe iris disease by 12 mos.
Consistent with the iris disease, ocular hypertension
occurred in mice of all genotypes as measured between 8
and 12 mos (Fig. 3). In all groups of mice, IOP distribu-
tions were closely matched with a similar range of IOP
levels until 12 mos, an age when levels of IOP start to
decrease in this model25. Declining IOP was most evident
in D2.Jnk2−/−mice compared with controls; however, this
difference was not significant (P= 0.052). Overall, these
data indicate that deletion of Jnk2 or Jnk3 does not alter
the iris disease and IOP insult in D2 mice.
Jnk2 deficiency increases susceptibility to glaucomatous
optic nerve damage
Key degenerative features of glaucoma include selective
loss of RGCs, cupping of the optic disc, and degeneration
of the optic nerve. Elevated IOP in wild-type D2 mice (D2.
Jnk2+/+Jnk3+/+) leads to a well-characterized glaucoma
with these key features25. To determine whether D2.
Jnk2−/− and D2.Jnk3−/− mice developed glaucoma, the
gross anatomy of their retinas and optic nerves were
examined. At 6 mos of age, retina and ONH anatomy was
normal in D2.Jnk2−/− and D2.Jnk3−/− eyes (n= 6 eyes/
genotype, Fig. 4a). At 12 mos, D2.Jnk2−/− and D2.Jnk3−/−
eyes with optic nerve degeneration all exhibited the hall-
mark features of glaucomatous degeneration with no
obvious differences to those observed in D2 mice (n= 6
eyes/genotype, Fig. 4b).
The degree of optic nerve degeneration was determined
in larger numbers of mice by analyzing optic nerve cross-
sections from mice aged between 9 and 13 mos (see
Materials and methods for details of damage determina-
tion). Consistent with IOP elevation, the number of eyes
with optic nerve degeneration increased with age for all
genotypes (Fig. 5). At each time point, there was no
Fig. 2 Jnk genotype has no affect on iris disease. Images of eyes were taken using a slit lamp biomicroscope. a Representative broad beam
images demonstrating similar iris abnormalities in mice of all genotypes. b Representative images demonstrating the similar transillumination defects
resulting from iris depigmentation in D2, D2.Jnk2−/−, and D2.Jnk3−/− mice
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significant difference in the distribution of injury between
optic nerves from D2.Jnk3−/− and control mice. Thus,
complete absence of Jnk3, either alone or in combination
with a single, heterozygous, null allele of Jnk2, did not
affect optic nerve degeneration. In contrast, in the 9–10
mos group significantly more D2.Jnk2−/− optic nerves
developed glaucomatous damage than control D2 optic
nerves (39% vs. 22% respectively; n= 60 eyes/genotype,
P < 0.001; Fig. 5a). The increased susceptibility was
still present in 10- to 11-month group, with, 73% of
D2.Jnk2−/− eyes having optic nerve damage compared
with 48% of control D2 eyes (n= 80 eyes/genotype,
Fig. 3 Deficiency of Jnk2 or Jnk3 does not alter intraocular pressure profiles in D2 mice. IOP elevation occurs in Jnk2 and Jnk3-deficient mice at
8.5 mos a, 10.0 mos b, and 12.0 mos c. IOP elevations sufficient to cause glaucoma were observed in mice of all genotypes. No significant differences
were found when comparing Jnk-deficient with control D2 mice (n= 40 per group, P > 0.05 in each comparison. However, at 12 mos Jnk2-deficient
mice tended to have lower IOP than controls (n= 42, P= 0.052). IOP levels start to decline in D2 mice at 12 mos due to ciliary body degeneration
and decreased production of aqueous humor. These data do not exclude a role for JNK2 in lessening this late disease process in the ciliary body, but
this IOP difference may also be due to chance variation. In the boxplot, the boxes define the 25th and 75th percentiles. The black line in each box
represents the median value. The red diamonds indicate the mean value and the 95% CI. The full range of the data points is also depicted
Fig. 4 Histological assessment of retina and optic nerve. Representative images from H&E-stained ocular cross-sections and PPD stained optic
nerves are shown for unaffected eyes (6 months of age) a, and severely affected eyes (12 months of age) b. These images demonstrate the hallmark
degenerative features of glaucoma including RGC layer (GCL) neuron loss in the retina, nerve fiber layer thinning (compare arrowheads in a and b),
optic disc cupping (arrow), and sick and degenerating axons (darkly stained dots), axon loss and glial scarring (asterisks) in the optic nerve. Scale bars:
50 μm (retina), 100 μm (optic nerve head), 25 μm (optic nerve)
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P < 0.001, Fig. 5b). In the 12- to 13-month group, a time
point when the vast majority of D2 mice that will develop
glaucomatous neurodegeneration have already done so
(and so used as an end stage)25, there was no difference
between genotypes (n= 45 eyes/genotype, Fig. 5c). Thus,
the absence of Jnk2 is associated with increased suscept-
ibility to ocular hypertension-induced optic nerve damage
(by increasing the likelihood of developing damage at
earlier ages with shorter exposure to high IOP).
Loss of Jnk3 increases optic nerve damage in Jnk2−/− mice
Eyes of D2.Jnk2−/−Jnk3−/− mice developed ocular
hypertension and optic nerve damage consistent with
glaucoma as for other genotypes (Fig. 6). IOP levels in D2.
Jnk2−/− and D2.Jnk2−/−3−/− mice were closely matched
until 12 mos, when IOP in more D2.Jnk2−/− eyes had
decreased (see above). IOPs profiles of D2.Jnk2−/−3−/−
eyes closely resembled those of wild-type, heterozygous,
and D2.Jnk3−/− mice (compare with Fig. 3c). The natural
decline in IOP starting at 12 mos was not affected by
combined Jnk2 and Jnk3 deficiency. The combination of
Jnk2 and Jnk3 deficiencies had a small effect on optic
nerve damage compared with Jnk2 deficiency alone. In
aggregate, between 9 and 13 mos in these age- and sex-
matched groups, more D2.Jnk2−/−Jnk3−/− eyes had a
severely damaged optic nerve than D2.Jnk2−/− eyes (107
Fig. 5 Jnk2 deficiency increases optic nerve vulnerability to high IOP. The severity of optic nerve damage was determined using PPD stained
cross-sections (see Materials and methods for details) at 9–10 mos a, > 10–11 mos b, and 12–13 mos c. Nerves were determined to have no
glaucomatous nerve damage (no or early, NOE—no glaucoma based on nerve damage but called NOE as some of these eyes have early
transcriptional changes that precede degeneration30), moderate disease (MOD) or severe disease (SEV). An increased number of eyes from Jnk2 mice
had glaucomatous nerve damage compared with control D2 mice at 9.5 and 10.5 mos. ***P < 1 × 10−5
Fig. 6 Jnk3 deficiency subtly exacerbates glaucoma in mice lacking Jnk2. a–c IOP elevations sufficient to cause glaucoma occurred for both
genotypes with no significant differences between genotypes at 8 and 10.5 mos. At 12 mos, the difference between Jnk2−/− and Jnk2−/− Jnk3−/−
genotypes was due to the IOP decrease observed in Jnk2 only deficient mice (P= 0.042). The IOP levels in mice with combined Jnk2 and 3
deficiencies closely resembled those of wild-type, heterozygous, and Jnk3-deficient mice (compare with Fig. 3c). Thus, the greater decrease in IOP in
the Jnk2−/− mice may be due to chance, as it is hard to reconcile why the additional deficiency of Jnk3 in Jnk2−/− Jnk3−/− mutant mice would
prevent it. d-f The severity of optic nerve damage was determined using PPD stained cross-sections (see Materials and methods for details). Data for
D2.Jnk2−/− mice are the same data as in Fig. 5 as mice of all genotypes were produced in the same litters and examined at the same time
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Jnk2−/−3−/− compared with 89 Jnk2−/− eyes; n= 185
eyes/genotype, P= 0.007). Based on these data, both Jnk2
and Jnk3 appear to influence glaucoma pathogenesis in
D2 mice.
JNK2 and JNK3 are not necessary for RGC death in
glaucoma
Recently, Jun deficiency was shown to lessen RGC
death after both mechanical optic nerve injury and in
ocular hypertensive D2 mice with optic nerve
damage13,15. Furthermore, after mechanical optic nerve
injury, JUN activation has been shown to be dependent
on JNK2 and JNK313,15. To determine whether Jnk2 and
Jnk3 are required for JUN phosphorylation and RGC
death in glaucoma, we assessed pJUN immunoreactivity
and RGC soma loss in D2.Jnk2−/−Jnk3−/− mice. At 10
mos, we detected pJUN in 6 out of 6 D2.Jnk2−/−Jnk3−/−
retinas and 6 out of 6 control D2 retinas examined
(Fig. 7a). At 12–13 mos, RGC soma loss as assessed by
counts of β-tubulin-positive RGCs was observed in 5 out
of 5 D2.Jnk2−/−Jnk3−/− eyes with severe optic
nerve damage (Fig. 7b). Similar loss of RGC somas
was observed in D2, D2.Jnk2−/−, D2.Jnk3−/−, and
D2.Jnk2−/−Jnk3−/− eyes corresponding with severe
optic nerve damage (Fig. 7c). These results indicate that
complete disruption of Jnk2 and Jnk3 is not sufficient to
prevent JUN activation in RGCs or RGC death after an
ocular hypertensive insult.
Discussion
The stress-activated JNK signaling pathway promotes
neurodegeneration in many systems and, thus, is widely
considered an attractive target for neuroprotective
therapies. The JNK pathway is known to promote axon
degeneration and cause RGC death in settings with acute
axon injury13–18, but was not tested in an age-related,
ocular hypertensive model of glaucoma. Here it is
demonstrated that activation of JNK2 and JNK3 are not
required for glaucomatous degeneration in D2 mice.
Instead, in the absence of JNK2, or both JNK2 and 3, there
is an increase in ocular hypertension-induced neurode-
generation. An important implication of these data is that
in a complex natural disease, manipulating JNK2 has an
impact on disease outcomes unrelated to its role in
directly activating soma or axon degeneration pathways.
The similar localization of pJNK observed in the ONH
after mechanical optic nerve injury14 and in glaucoma
(Fig. 1b) is consistent with the hypothesis that axon injury
activates JNK in glaucoma. The importance of JNK sig-
naling in RGC death in glaucoma and after optic nerve
injury is supported by the increased RGC survival seen in
these same two experimental models in Jun-deficient
mice13,15. Thus, it is surprising that combined Jnk2 and 3
deficiencies did not protect RGCs from death in glaucoma
as it did after mechanical optic nerve injury. Our analyses
of JNK signaling support the idea that differences occur at
the level of JUN activation. Whereas JUN activation
Fig. 7 JNK2 and JNK3 are not necessary for RGC somal
degeneration in glaucoma. a The JNK target JUN is known to
promote RGC apoptosis in D2 glaucoma15. Double deficiency of Jnk2
and Jnk3 did not prevent accumulation of phosphorylated JUN (pJUN)
immunoreactivity (red) at 10 mos. pJUN was detected by
immunofluorescence in retinal flat mounts. b β-Tubulin is an RGC-
specific marker in the retina and was used to label RGCs in retinal flat
mounts at 12 mos. Representative images show loss of RGCs in eyes
with severe optic nerve degeneration compared with healthy (NOE)
eyes. Occasional RGCs have higher β-tubulin immunoreactivity (bright
cells). c Quantification of β-tubulin-positive cells suggests that Jnk2
and Jnk3 deficiency did not affect somal degeneration of RGCs in eyes
with severe optic nerve loss. RGC counts were similar in NOE eyes for
all genotypes (represented together as All)
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appears to be dependent on Jnk2 and 3 after mechanical
optic nerve injury13, JUN activation due to ocular hyper-
tension in D2 mice still occurred in RGC somas in the
absence of JNK2 and 3 (Fig. 7a). The antibody used in this
study detected JUN phosphorylation at the serine 63
residue, a phosphorylation site that is primarily specific to
the kinase activity of JNK1, JNK2, and JNK3 after
insults31. These data show that JNK2 and 3 are not
required for JUN activation within RGCs, and they sug-
gest a role for JNK1 in glaucoma. It is unclear if the
involvement of JNK1 specific to D2 glaucoma is the result
of the differing nature of the insult (progressive, chronic
ocular hypertension compared with acute and sudden
mechanical axonal injury), the potential for ocular
hypertension to directly perturb pathways in more than
just RGC axons, the involvement of other cells besides
RGCs, or the absence of JNK2 and 3. In future studies, it
will be important to understand why the mechanism of
JUN activation appears to differ between the contexts of a
natural, age-related, progressive ocular hypertensive
injury and an experimentally induced mechanical axonal
injury. Nevertheless, these data highlight the importance
of testing neuroprotective treatments in an age-related,
chronic, ocular hypertensive model of glaucoma.
This work uncovered a novel neuroprotective function
of JNK2 and provided an example of unequal contribu-
tions by JNK2 and JNK3 to glaucoma pathogenesis. Here,
mice completely deficient in Jnk2 progressed more quickly
from onset of ocular hypertension to glaucomatous neu-
rodegeneration than wild-type, Jnk2 and Jnk3 double
heterozygous, or Jnk3-deficient mice. Although unlikely,
as no heterozygous effects are reported, smaller effects
associated with copy number of Jnk2 and Jnk3 cannot be
dismissed due to the inclusion of Jnk2 or Jnk3 hetero-
zygous mice in the study. Combining Jnk2 and Jnk3
deficiencies did have a small additional effect on optic
nerve damage above the level of Jnk2 deficiency. Overall,
these data are consistent with JNK2 being a major med-
iator of neuroprotective JNK signaling after an ocular
hypertensive injury. The prominent role of JNK2 may be
related to a function of JNK2 that is not currently asso-
ciated with other JNKs. Our data indicate that Jnk2 was
significantly downregulated in RGCs at a pre-degenerative
stage of glaucoma in D2 mice (Fig. 1a). This early stage is
marked by transcriptional responses related to metabolic
and mitochondrial dysfunction within RGCs29,32–34. Of
note, a unique function of JNK2 is to regulate mitophagy,
in part through controlling degradation of smARF (a gene
product of Cdnk2b) and indirectly p6235. Complete loss of
JNK2 in RGCs may disrupt mitophagy early in glaucoma.
Alternatively, JNK-deficient mice have altered immune
responses36–38 and inflammatory responses in the nervous
system39,40. Thus, disruption of Jnk2 may affect how these
types of responses contribute to glaucoma pathogenesis.
In the experiments described here, mice carried a germ-
line disruption of Jnk2. As the expression of Jnk2 is ubi-
quitous in mammalian cells41, its absence may have
affected the development, physiology, or stress response
in any glaucoma-relevant cell type. Experiments that use
cell type-specific disruption of Jnk2 in RGCs and other
glaucoma-relevant cells are necessary to further under-
stand the role of JNK2 as a susceptibility factor for
glaucoma.
In conclusion, this study provides further evidence
implicating stress-activated kinases in the JNK family as
modulators of RGC survival or death after axon injury and
in glaucoma. The specific mechanisms that are impacted
by the injury type and the final outcome is likely to be
impacted by the competing pro-survival and pro-death
effects of JNK activation. To effectively target JNK as a
neuroprotective therapy, the pleiotropic effects of JNK
isoforms need to be identified and specifically targeted.
Materials and methods
Mice
All experiments were conducted in accordance with the
Association for Research in Vision and Ophthalmology
statement on the use of animals in ophthalmic research
and approved by The Jackson Laboratory Institutional
Animal Care and Use Committee. Mice were housed with
a 14-h light/10-h dark cycle and provided food and water
ad libitum42. DBA/2J (D2), D2-Gpnmb+/J (D2-Gpnmb+),
and mice carrying null alleles of Jnk2 (Jnk2-; D2.129(B6)-
Mapk9<tm1Flv>/SjJ) and Jnk3 (Jnk3-; D2.129S1(B6)-
Mapk10<tm1Flv>/SjJ) backcrossed to D2 for 13 generations
have been previously described4,13,24,43. D2-Gpnmb+ mice
are a substrain of D2 mice that have normal IOP at all
ages and do not develop glaucoma44. Experimental
cohorts of mice were generated using intercrosses of D2.
Jnk2+/- Jnk3+/- (double heterozygous) mice. Mice referred
to as control D2 mice include mice with wild-type (+/+)
and heterozygous (+/-) genotypes for Jnk2 and Jnk3 (e.g.,
Jnk2+/+Jnk3+/+, Jnk2+/+Jnk3+/−, Jnk2+/−Jnk3+/+, and
Jnk2+/−Jnk3+/−). Mice with genotypes of Jnk2−/− include
mice with Jnk3+/+ and Jnk3+/− genotypes. Mice with
genotypes of Jnk3−/− include mice with Jnk2+/+ and
Jnk2+/- genotypes.
Clinical exams and intraocular pressure measurement
D2 mice develop a form of pigmentary glaucoma. In D2
eyes, elevated IOP occurs secondary to a depigmenting
iris disease24,25,42. Iris disease and intraocular pressure
were evaluated in mutant mice and littermate control D2
mice using previously described methods23,24,45. Iris dis-
ease was assessed at 2-month intervals starting at
6 months of age until experimental completion in > 40
eyes of each genotype. Intraocular pressure was measured
at 8.5, 10.0, and 12.0 months of age.
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Assessment of retina and optic nerve damage by histology
Mice were analyzed as three age groups: 9–10 mos,
>10–11 mos, and 12–13 mos. Mice of each genotype
within each age bin were age and sex matched. The
method of preparing, staining, and analyzing plastic sec-
tions of retinas and optic nerves for damage has been
previously described and validated4,8,25,30,46,47. Retinal
cross-sections were stained with hematoxylin and eosin
(H&E). Cross-sections of optic nerve were stained with
paraphenylenediamine (PPD), which stains all myelin
sheaths, but darkly stains the axoplasm of injured or dying
axons. Individual damaged axons are readily identified
within a generally healthy nerve. Two investigators
assigned one of three damages level to each nerve. The
investigators were masked to age, genotype, and damage
level assigned by the other investigator. In rare cases of
disagreement, a third masked investigator acted as a tie-
breaker. Nerves with no or early glaucoma (NOE) have no
detectable glaucomatous damage and are indistinguish-
able from D2.Gpnmb+ nerves. Moderately (MOD) affec-
ted nerves had readily detectable degenerating axons
(average 30% axon loss) as marked by darkly stained
axoplasm; however, the majority of axons were still
healthy. Severely (SEV) affected nerves have >50% axon
loss and prominent gliosis. Axon numbers are sig-
nificantly different between optic nerves of each damage
level4,8,25,30,46,47. To be used for histology or RGC counts
representing severe glaucoma, a retina had to be asso-
ciated with an optic nerve judged to have >95% of axons
lost (i.e., entirely gliotic with few remaining axons).
Immunohistochemistry
Eyes were fixed in 4% paraformaldehyde and subse-
quently either cryoprotected in 30% sucrose and frozen or
the retinas were dissected for use in flat mounts. For
cryosection immunostaining, slides were blocked in 10%
horse serum in 0.1% Triton X-100 in phosphate-buffered
saline (PBS) (PBST) for 2 h, incubated in primary antibody
solutions overnight, and secondary antibody solutions for
2 h. Primary antibodies (rabbit anti-phosphorylated pan-
JNK, pJNK, Cell Signaling, #4668) were diluted in PBST
containing 2% goat serum. Alexafluor-conjugated sec-
ondary antibodies (Invitrogen) were diluted in PBST
(AF488 and AF568) and nuclei were counterstained with
4,6-diamidino-2-phenylindole (DAPI). For flat mount
immunostaining, retinas were blocked in 0.3% Triton X-
100 in PBS containing 10% goat serum for 3–4 h, incu-
bated in primary antibody solutions overnight and sec-
ondary antibody solutions for 3–4 h. Primary antibodies
(rabbit anti-p-cJUN, Abcam, #ab32385, mouse anti-β-
tubulin, Covance, #MMS-435P) were diluted in 0.3%
Triton X-100 in PBS, and Alexafluor-conjugated sec-
ondary antibodies (Invitrogen) diluted in PBST for 24 h at
4°C. Following antibody incubations and washes, the
retinas were mounted on slides in aquamount, cover-
slipped, and sealed with nail polish. Images of slides were
taken using a Zeiss AxioImager.
RNA-sequencing dataset analysis
The RGC transcriptome data used was from publically
available RNA-sequencing data sets generated by our lab:
GEO accession number GSE9065429. Differential gene
expression analysis was performed in edgeR v3.10.548 and
plotted using custom R scripts.
Statistical analyses
For IOP measurements, 40 eyes per genotype were
assessed at each time point. Statistical analysis was per-
formed using Student’s t-test and Holm-corrected
P-values with P < 0.01 considered significant. Optic nerve
disease stage profiles were compared between genotypes
using Fisher exact and Holm-corrected P-values with
P < 0.01 considered significant. Differential expression
analysis of RNA-seq transcripts was adjusted for multiple
testing using a FDR (q). Genes were considered to be
significantly differentially expression at an FDR < 0.05.
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